ROTE WILLIAM E. 4
4 · Travere Therapeutics, Inc. · Filed May 5, 2025
Insider Transaction Report
Form 4
ROTE WILLIAM E.
Chief Research Officer
Transactions
- Exercise/Conversion
Common Stock
2025-05-02+4,920→ 103,439 total - Sale
Common Stock
2025-05-05$21.05/sh−3,198$67,318→ 100,241 total - Exercise/Conversion
Performance-based restricted stock units
2025-05-02−4,920→ 4,920 total→ Common Stock (4,920 underlying)
Footnotes (3)
- [F1]On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.
- [F2]Each PSU represents a contingent right to receive one share of the common stock of the Issuer.
- [F3]This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.